Search

Your search keyword '"Vito, Lampasona"' showing total 57 results

Search Constraints

Start Over You searched for: Author "Vito, Lampasona" Remove constraint Author: "Vito, Lampasona" Topic business.industry Remove constraint Topic: business.industry
57 results on '"Vito, Lampasona"'

Search Results

1. No Evidence of Long-Term Disruption of Glycometabolic Control After SARS-CoV-2 Infection

2. Rapamycin Plus Vildagliptin to Recover β-Cell Function in Long-Standing Type 1 Diabetes: A Double-Blind, Randomized Trial

3. Seasonal betacoronavirus antibodies expansion post BNT161b2 vaccination associates with reduced SARS-CoV-2 VoCs neutralization

4. Preexisting diabetes and COVID-associated hyperglycaemia in patients with COVID-19 pneumonia

5. A Public Health Antibody Screening Indicates a Marked Increase of SARS-CoV-2 Exposure Rate in Children during the Second Wave

6. COVID-BioB Cohort Study: the neutralizing antibody response to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for virus control and survival

7. A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis

8. Young infants exhibit robust functional antibody responses and restrained IFN-γ production to SARS-CoV-2

9. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival

10. Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia

11. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain

12. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study

13. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with clinical outcome

14. Issue Information

15. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay

16. The first 142 amino acids of glutamate decarboxylase do not contribute to epitopes recognized by autoantibodies associated with Type 1 diabetes

17. A novel LIPS assay for insulin autoantibodies

18. P.168: Biofabrication of a Functional Vascularized Endocrine Pancreas (VEP) for Type 1 Diabetes

19. Autoantibodies against zinc transporter 8 further stratify the autoantibody-defined risk for type 1 diabetes in a general population of schoolchildren and have distinctive isoform binding patterns in different forms of autoimmune diabetes: results from the Karlsburg Type 1 Diabetes Risk Study

20. Public health antibody screening indicates a six-fold higher SARS-CoV-2 exposure rate than reported cases in children

21. Cell-based assays for the detection of MOG antibodies: a comparative study

22. Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report

23. Intrinsic factor autoantibodies by luminescent immuno-precipitation system in patients with corpus atrophic gastritis

24. Autoantibodies Toward ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase Are Reliable Serological Pre-endoscopic Markers of Corpus Atrophic Gastritis

25. Treatment with rapamycin can restore regulatory T-cell function in IPEX patients

26. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes:Action LADA 12

27. Reactivity to N-Terminally Truncated GAD65(96–585) Identifies GAD Autoantibodies That Are More Closely Associated With Diabetes Progression in Relatives of Patients With Type 1 Diabetes

28. Study of 2009 H1N1 pandemic influenza virus as a possible causative agent of diabetes

29. Alloantibody and Autoantibody Monitoring Predicts Islet Transplantation Outcome in Human Type 1 Diabetes

30. Islet Autoantibodies

31. Autoantibody binding in liquid phase to IL-2 in human sera is not type 1 diabetes specific

32. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes

33. Treatment of Thyroid-Associated Orbitopathy With Rituximab—A Novel Therapy for an Old Disease: Case Report and Literature Review

34. Zinc Transporter 8 Antibodies Complement GAD and IA-2 Antibodies in the Identification and Characterization of Adult-Onset Autoimmune Diabetes

35. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial

36. Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes

37. No evidence of diabetes-specific CD38 (ADP ribosil cyclase/cyclic ADP-ribose hydrolase) autoantibodies by liquid-phase immunoprecipitation

38. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease

39. Diabetes Antibody Standardization Program

40. Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients

41. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects

42. No evidence of enteroviruses in the intestine of patients with type 1 diabetes

43. Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant

44. Diabetes antibody standardization program: First proficiency evaluation of assays for autoantibodies to zinc transporter 8

45. Developing and Validating High Sensitivity/Specificity Autoantibody Assays

46. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients

47. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77

48. Autoantibodies

49. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

50. Antibodies to tissue transglutaminase C in type I diabetes

Catalog

Books, media, physical & digital resources